✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Afuresertib is an investigational drug.
There have been 14 clinical trials for Afuresertib. The most recent clinical trial was a Phase 2 trial, which was initiated on June 9th 2020.
The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Endometrial Neoplasms. The leading clinical trial sponsors are Laekna Limited, GlaxoSmithKline, and Novartis Pharmaceuticals.
There are fifty-eight US patents protecting this investigational drug and six hundred and thirty-three international patents.
Recent Clinical Trials for Afuresertib
|Human Mass Balance and Biotransformation Study of [14C]Afuresertib||Laekna Limited||Phase 1|
|Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1||Laekna Limited||Phase 1/Phase 2|
|Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer||Laekna LLC||Phase 1|
Top disease conditions for Afuresertib
Top clinical trial sponsors for Afuresertib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Afuresertib||See Plans and Pricing||Treatment of ophthalmic conditions by selectively removing senescent cells from the eye||Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN)||See Plans and Pricing|
|Afuresertib||See Plans and Pricing||.beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof||Quadriga Biosciences, Inc. (Los Altos, CA)||See Plans and Pricing|
|Afuresertib||See Plans and Pricing||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||See Plans and Pricing|
|Afuresertib||See Plans and Pricing||Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population||UNITY BIOTECHNOLOGY, INC. (Brisbane, CA) BUCK INSTITUE FOR RESEARCH ON AGING (Novato, CA) MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (Rochester, MN)||See Plans and Pricing|
|Afuresertib||See Plans and Pricing||Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways||Asana BioSciences, LLC (Lawrenceville, NJ)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Afuresertib||Australia||AU2015211021||2034-01-28||See Plans and Pricing|
|Afuresertib||Australia||AU2020244600||2034-01-28||See Plans and Pricing|
|Afuresertib||Brazil||BR112016017564||2034-01-28||See Plans and Pricing|
|Afuresertib||Canada||CA2939121||2034-01-28||See Plans and Pricing|
|Afuresertib||Canada||CA3100140||2034-01-28||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|